Deal activity in the medtech contract development and manufacturing organization (CDMO) sector was sustained in H1 2024, despite a decline in the number of transactions compared to H1 2023. Against an uncertain macroeconomic backdrop, the market has continued to show resilience and a robust trajectory of industry consolidation.

For detailed insights on the current CDMO M&A landscape, download our analysis, which includes H1 2024 data on:

• Private equity exits
• M&A geography
• Targeted capabilities
• Emerging M&A trends